» Articles » PMID: 27757318

Adoptively Transferred Natural Killer Cells Maintain Long-term Antitumor Activity by Epigenetic Imprinting and CD4 T Cell Help

Overview
Journal Oncoimmunology
Date 2016 Oct 21
PMID 27757318
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Natural killer (NK) cell infusions can induce remissions in subsets of patients with different types of cancer. The optimal strategies for NK cell activation prior to infusion are still under debate. There is recent evidence that NK cells can acquire long-term functional competence by preactivation with the cytokines IL-12/15/18. The mechanisms supporting the maintenance of long-term NK cell antitumor activity are incompletely under-stood. Here, we show that NK cells preactivated with IL-12/15/18, but not with IL-15 alone, maintained high antitumor activity even 1 mo after transfer into lymphopenic RAG-2γc mice. The NK cell intrinsic ability for IFNγ production coincided with demethylation of the conserved non-coding sequence (CNS) 1 in the locus, previously shown to enhance transcription of . In a xenograft melanoma mouse model, human IL-12/15/18-preactivated NK cells rejected tumors more efficiently. In RAG-2γc mice, co-transfer of CD4 T cells further improved the long-term competence of NK cells for IFNγ production that was dependent on IL-2. CD4 T cell activation during homeostatic proliferation required macrophages and further promoted the long-term NK cell antitumor activity. Thus, NK cells can "remember" a previous exposure to cytokines by epigenetic imprinting resulting in a remarkable stability of the IFNγ-producing phenotype after adoptive transfer. In addition, our results support combination of cytokine-preactivated NK cells with CD4 T cell activation upon lymphopenic conditioning to achieve long-term NK cell effector function for cancer immunotherapy.

Citing Articles

From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy.

Laeremans T, Janssens A, Aerts J Immunotherapy. 2025; 17(2):133-145.

PMID: 39905963 PMC: 11901454. DOI: 10.1080/1750743X.2025.2460965.


Emerging Insights into Memory Natural Killer Cells and Clinical Applications.

Kokici J, Preechanukul A, Arellano-Ballestero H, Gorou F, Peppa D Viruses. 2024; 16(11).

PMID: 39599860 PMC: 11599065. DOI: 10.3390/v16111746.


A "Prime and Expand" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy.

Shrestha N, Dee M, Chaturvedi P, Leclerc G, Mathyer M, Dufour C Cancer Immunol Immunother. 2024; 73(9):179.

PMID: 38960949 PMC: 11222348. DOI: 10.1007/s00262-024-03765-8.


Deciphering CD4 T cell-mediated responses against cancer.

Kirkpatrick C, Lu Y Mol Carcinog. 2024; 63(7):1209-1220.

PMID: 38725218 PMC: 11166516. DOI: 10.1002/mc.23730.


Twenty-One Flavors of Type 1 Innate Lymphoid Cells with PD-1 (Programmed Cell Death-1 Receptor) Sprinkles.

Smith K, Sciume G, Amarnath S Discov Immunol. 2024; 2(1):kyad003.

PMID: 38567059 PMC: 10917210. DOI: 10.1093/discim/kyad003.


References
1.
Keppel M, Yang L, Cooper M . Murine NK cell intrinsic cytokine-induced memory-like responses are maintained following homeostatic proliferation. J Immunol. 2013; 190(9):4754-62. PMC: 3633638. DOI: 10.4049/jimmunol.1201742. View

2.
Szabo S, Sullivan B, Stemmann C, Satoskar A, Sleckman B, Glimcher L . Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science. 2002; 295(5553):338-42. DOI: 10.1126/science.1065543. View

3.
Kelly M, Zheng M, Ruan S, Kolls J, DSouza A, Shellito J . Memory CD4+ T cells are required for optimal NK cell effector functions against the opportunistic fungal pathogen Pneumocystis murina. J Immunol. 2012; 190(1):285-95. PMC: 3711123. DOI: 10.4049/jimmunol.1200861. View

4.
Dunn G, Koebel C, Schreiber R . Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006; 6(11):836-48. DOI: 10.1038/nri1961. View

5.
Velardi A . Natural killer cell alloreactivity 10 years later. Curr Opin Hematol. 2012; 19(6):421-6. DOI: 10.1097/MOH.0b013e3283590395. View